title: Anti-cell-associated glucosyltransferase immunoglobulin Y suppression of salivary mutans streptococci in healthy young adults.
abstract: BACKGROUND
  The authors evaluated the suppressive effects of lozenges containing egg yolk antibodies (that is, immunoglobulin Y [IgY]) against Streptococcus mutans cell-associated glucosyltransferase (CA-gtf) on oral colonization by mutans streptococci (MS) in healthy young adults.
  
  
  METHODS
  In a five-day double-masked placebo-controlled trial, young adult participants self-administered lozenges containing anti-CA-gtf IgY (Ovalgen DC, GHEN, Gifu-City, Japan) or a placebo at prescribed times each day. On the basis of bacterial colony counts of saliva cultures, the authors analyzed the pretrial and posttrial differences in levels of MS and total anaerobic bacteria among participants in the treatment (anti-CA-gtf IgY) and placebo groups and a control group.
  
  
  RESULTS
  Salivary MS scores in participants in the treatment group decreased significantly (P < .001), and the mean anaerobic bacterial count in the treatment group was not statistically different before and after the trial. In the placebo and control groups, posttrial changes in median MS scores and total salivary anaerobic bacterial counts were not statistically significant.
  
  
  CONCLUSIONS
  The results of the study show that lozenges containing anti-CA-gtf IgY can suppress oral colonization by MS in healthy young adults.
  
  
  CONCLUSIONS
  Lozenges containing anti-CA-gtf IgY may help reduce dental caries risk in humans.
authors.affiliation: Immunology Research Institute in Ghen, 839-1 Sano, Gifu-city, Japan. nguyen@ghen.co.jp
authors.forename: Sa V
authors.initials: SV
authors.lastname: Nguyen
authors.forename: Faustino C
authors.initials: FC
authors.lastname: Icatlo
authors.forename: Taku
authors.initials: T
authors.lastname: Nakano
authors.forename: Emiko
authors.initials: E
authors.lastname: Isogai
authors.forename: Kimiharu
authors.initials: K
authors.lastname: Hirose
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Mizugai
authors.forename: Michiyo
authors.initials: M
authors.lastname: Kobayashi-Sakamoto
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Isogai
authors.forename: Itsuo
authors.initials: I
authors.lastname: Chiba
mesh_terms: D000328:Adult; D000907:Antibodies, Bacterial / Q000008:administration & dosage / Q000627:therapeutic use*; D000918:Antibody Specificity / Q000276:immunology; D001421:Bacteria, Anaerobic / Q000302:isolation & purification; D001422:Bacterial Adhesion / Q000276:immunology; D058491:Bacterial Load; D004311:Double-Blind Method; D005260:Female; D005964:Glucosyltransferases / Q000276:immunology* / Q000302:isolation & purification; D006801:Humans; D007136:Immunoglobulins / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D010919:Placebos; D012463:Saliva / Q000382:microbiology*; D012703:Serotyping; D013291:Streptococcus / Q000145:classification; D013295:Streptococcus mutans / Q000145:classification / Q000276:immunology* / Q000302:isolation & purification; D013607:Tablets; D055815:Young Adult
chemical_list: D000907:Antibodies, Bacterial; C016512:IgY; D007136:Immunoglobulins; D010919:Placebos; D013607:Tablets; D005964:Glucosyltransferases